202 related articles for article (PubMed ID: 31852219)
1. MicroRNA-144 Silencing Protects Against Atherosclerosis in Male, but Not Female Mice.
Cheng J; Cheng A; Clifford BL; Wu X; Hedin U; Maegdefessel L; Pamir N; Sallam T; Tarling EJ; de Aguiar Vallim TQ
Arterioscler Thromb Vasc Biol; 2020 Feb; 40(2):412-425. PubMed ID: 31852219
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-19b promotes macrophage cholesterol accumulation and aortic atherosclerosis by targeting ATP-binding cassette transporter A1.
Lv YC; Tang YY; Peng J; Zhao GJ; Yang J; Yao F; Ouyang XP; He PP; Xie W; Tan YL; Zhang M; Liu D; Tang DP; Cayabyab FS; Zheng XL; Zhang DW; Tian GP; Tang CK
Atherosclerosis; 2014 Sep; 236(1):215-26. PubMed ID: 25084135
[TBL] [Abstract][Full Text] [Related]
3. Diosgenin inhibits atherosclerosis via suppressing the MiR-19b-induced downregulation of ATP-binding cassette transporter A1.
Lv YC; Yang J; Yao F; Xie W; Tang YY; Ouyang XP; He PP; Tan YL; Li L; Zhang M; Liu D; Cayabyab FS; Zheng XL; Tang CK
Atherosclerosis; 2015 May; 240(1):80-9. PubMed ID: 25765596
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA 302a is a novel modulator of cholesterol homeostasis and atherosclerosis.
Meiler S; Baumer Y; Toulmin E; Seng K; Boisvert WA
Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):323-31. PubMed ID: 25524771
[TBL] [Abstract][Full Text] [Related]
5. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis.
Rayner KJ; Sheedy FJ; Esau CC; Hussain FN; Temel RE; Parathath S; van Gils JM; Rayner AJ; Chang AN; Suarez Y; Fernandez-Hernando C; Fisher EA; Moore KJ
J Clin Invest; 2011 Jul; 121(7):2921-31. PubMed ID: 21646721
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-20a/b regulates cholesterol efflux through post-transcriptional repression of ATP-binding cassette transporter A1.
Liang B; Wang X; Song X; Bai R; Yang H; Yang Z; Xiao C; Bian Y
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):929-938. PubMed ID: 28602962
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr-/- mice--brief report.
Rotllan N; Ramírez CM; Aryal B; Esau CC; Fernández-Hernando C
Arterioscler Thromb Vasc Biol; 2013 Aug; 33(8):1973-7. PubMed ID: 23702658
[TBL] [Abstract][Full Text] [Related]
8. Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144.
Ramírez CM; Rotllan N; Vlassov AV; Dávalos A; Li M; Goedeke L; Aranda JF; Cirera-Salinas D; Araldi E; Salerno A; Wanschel A; Zavadil J; Castrillo A; Kim J; Suárez Y; Fernández-Hernando C
Circ Res; 2013 Jun; 112(12):1592-601. PubMed ID: 23519695
[TBL] [Abstract][Full Text] [Related]
9. microRNA-185 modulates low density lipoprotein receptor expression as a key posttranscriptional regulator.
Jiang H; Zhang J; Du Y; Jia X; Yang F; Si S; Wang L; Hong B
Atherosclerosis; 2015 Dec; 243(2):523-32. PubMed ID: 26523989
[TBL] [Abstract][Full Text] [Related]
10. microRNAs in lipoprotein metabolism and cardiometabolic disorders.
Rotllan N; Price N; Pati P; Goedeke L; Fernández-Hernando C
Atherosclerosis; 2016 Mar; 246():352-60. PubMed ID: 26828754
[TBL] [Abstract][Full Text] [Related]
11. Liver ABCA1 deletion in LDLrKO mice does not impair macrophage reverse cholesterol transport or exacerbate atherogenesis.
Bi X; Zhu X; Duong M; Boudyguina EY; Wilson MD; Gebre AK; Parks JS
Arterioscler Thromb Vasc Biol; 2013 Oct; 33(10):2288-96. PubMed ID: 23814116
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-144 regulates hepatic ATP binding cassette transporter A1 and plasma high-density lipoprotein after activation of the nuclear receptor farnesoid X receptor.
de Aguiar Vallim TQ; Tarling EJ; Kim T; Civelek M; Baldán Á; Esau C; Edwards PA
Circ Res; 2013 Jun; 112(12):1602-12. PubMed ID: 23519696
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/- mice.
Horie T; Baba O; Kuwabara Y; Chujo Y; Watanabe S; Kinoshita M; Horiguchi M; Nakamura T; Chonabayashi K; Hishizawa M; Hasegawa K; Kume N; Yokode M; Kita T; Kimura T; Ono K
J Am Heart Assoc; 2012 Dec; 1(6):e003376. PubMed ID: 23316322
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides.
Rayner KJ; Esau CC; Hussain FN; McDaniel AL; Marshall SM; van Gils JM; Ray TD; Sheedy FJ; Goedeke L; Liu X; Khatsenko OG; Kaimal V; Lees CJ; Fernandez-Hernando C; Fisher EA; Temel RE; Moore KJ
Nature; 2011 Oct; 478(7369):404-7. PubMed ID: 22012398
[TBL] [Abstract][Full Text] [Related]
15. miRNA Targeting of Oxysterol-Binding Protein-Like 6 Regulates Cholesterol Trafficking and Efflux.
Ouimet M; Hennessy EJ; van Solingen C; Koelwyn GJ; Hussein MA; Ramkhelawon B; Rayner KJ; Temel RE; Perisic L; Hedin U; Maegdefessel L; Garabedian MJ; Holdt LM; Teupser D; Moore KJ
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):942-951. PubMed ID: 26941018
[TBL] [Abstract][Full Text] [Related]
16. miR33 inhibition overcomes deleterious effects of diabetes mellitus on atherosclerosis plaque regression in mice.
Distel E; Barrett TJ; Chung K; Girgis NM; Parathath S; Essau CC; Murphy AJ; Moore KJ; Fisher EA
Circ Res; 2014 Oct; 115(9):759-69. PubMed ID: 25201910
[TBL] [Abstract][Full Text] [Related]
17. miR-223 Exerts Translational Control of Proatherogenic Genes in Macrophages.
Nguyen MA; Hoang HD; Rasheed A; Duchez AC; Wyatt H; Cottee ML; Graber TE; Susser L; Robichaud S; Berber İ; Geoffrion M; Ouimet M; Kazan H; Maegdefessel L; Mulvihill EE; Alain T; Rayner KJ
Circ Res; 2022 Jun; 131(1):42-58. PubMed ID: 35611698
[TBL] [Abstract][Full Text] [Related]
18. Macrophage miR-34a Is a Key Regulator of Cholesterol Efflux and Atherosclerosis.
Xu Y; Xu Y; Zhu Y; Sun H; Juguilon C; Li F; Fan D; Yin L; Zhang Y
Mol Ther; 2020 Jan; 28(1):202-216. PubMed ID: 31604677
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-320b Modulates Cholesterol Efflux and Atherosclerosis.
Lu X; Yang B; Yang H; Wang L; Li H; Chen S; Lu X; Gu D
J Atheroscler Thromb; 2022 Feb; 29(2):200-220. PubMed ID: 33536383
[TBL] [Abstract][Full Text] [Related]
20. Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice.
Marquart TJ; Wu J; Lusis AJ; Baldán Á
Arterioscler Thromb Vasc Biol; 2013 Mar; 33(3):455-8. PubMed ID: 23288159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
